[
  {
    "info": {
      "NCT": "NCT04260126",
      "Protocol_No": "PDS0101-HNC-201",
      "jit": "Tempus",
      "trial_name": "PDS Versitile-002"
    },
    "disease": {
      "summary": "Metastatic Head and Neck Cancer | Recurrent Head and Neck Cancer | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Neoplasms, Head and Neck",
      "details": [
        {
          "code": "Cervix (CERVIX)",
          "selection": "include",
          "stage": "Recurrent;Metastatic"
        },
        {
          "code": "Head and Neck (HEAD_NECK)",
          "selection": "include",
          "stage": "Recurrent;Metastatic"
        },
        {
          "code": "Head and Neck Squamous Cell Carcinoma (HNSC)",
          "selection": "include",
          "stage": "Recurrent;Metastatic"
        }
      ]
    },
    "query": {
      "nct": "NCT04260126",
      "title": "Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC",
      "current_status": "Recruiting",
      "status_verif_date": "August 2022",
      "last_update_date": "August 26, 2022",
      "trial_hold_status": "closed",
      "sponsor": "PDS Biotechnology Corp.",
      "brief_summary": "VERSATILE-002 is a Phase 2, open-label, multicenter study of the efficacy and safety of PDS0101 administered in combination with pembrolizumab in adults with HPV16 and PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).",
      "conditions": "Metastatic Head and Neck Cancer | Recurrent Head and Neck Cancer | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Neoplasms, Head and Neck",
      "type": "Interventional",
      "phase": "Phase 2",
      "arm": [
        {
          "ArmID": "1",
          "cohortlabel": "Pembrolizumab and PDS0101",
          "drug": "Combination Product: Pembrolizumab and PDS0101",
          "arm_type": "Experimental",
          "line_of_therapy": "Not available",
          "arm_hold_status": "closed",
          "biomarker": [
            {
              "cohort": "Pembrolizumab and PDS0101",
              "Gene": "Not available",
              "Gene2": "Not available",
              "Type": "PD-L1",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "positive",
              "summary": "PD-L1 positive (CPS) â‰¥1 "
            }
          ]
        }
      ],
      "docs": "<a href=\"https://therapies.securetempus.com/\" target=\"_blank\">Tempus<\/a>",
      "locations": "Sioux Falls SD",
      "doclastupdate": "2023-01-30",
      "min_age": "18 Years",
      "gender": "All",
      "link": "<a href=\"https://clinicaltrials.gov/ct2/show/NCT04260126\" target=\"_blank\">NCT04260126<\/a>"
    }
  }
]
